High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 637-646

  Rasmussen, Mads H ^a   Jensen, Niels F ^b   Tarpgaard, Line S ^c   Qvortrup, Camilla ^c   Rømer, Maria U ^b   Stenvang, Jan ^b   Hansen, Tine P ^c   Christensen, Lise L ^a   Lindebjerg, Jan ^d   Hansen, Flemming ^a   Jensen, Benny V ^e   Hansen, Torben F ^d   Pfeiffer, Per ^c   Brünner, Nils ^b   Ørntoft, Torben F ^a   Andersen, Claus L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d LILLEBAELT HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemotherapy resistance; Metastatic colorectal cancer; MicroRNA 625; Oxaliplatin; XELOX FOLFOX

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; MICRORNA; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; COLON CANCER; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION;

EID: 84878114067     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.016     Document Type: Article

References (44)

1. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers. 2010, 7:543-566.
2. Allen K.E., Weiss G.J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol. Cancer Ther. 2010, 9:3126-3136.
3. Andersen C.L., Jensen J.L., Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245-5250.
4. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
5. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat. Rev. Genet. 2011, 12:846-860.
6. Boni V., Bitarte N., Cristobal I., Zarate R., Rodriguez J., Maiello E., Garcia-Foncillas J., Bandres E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther. 2010, 9:2265-2275.
7. Chai H., Liu M., Tian R., Li X., Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim. Biophys. Sin (Shanghai) 2011, 43:217-225.
8. Christensen L.L., Tobiasen H., Holm A., Schepeler T., Ostenfeld M.S., Thorsen K., Rasmussen M.H., Birkenkamp-Demtroeder K., Sieber O.M., Gibbs P., Lubinski J., Lamy P., On behalf of the, C.s.g.S.L, Øster B., Hansen K.Q., Hagemann-Madsen R., Byskov K., Ørntoft T.F., Andersen C.L., The first authorship is shared by Lise Lotte, C., Heidi T. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int. J. Cancer 2012, [Epub ahead of print]. 10.1002/ijc.28010.
9. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18:2938-2947.
10. de Hoon M.J., Imoto S., Nolan J., Miyano S. Open source clustering software. Bioinformatics 2004, 20:1453-1454.
11. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
12. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
13. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004, 32:D109-D111.
14. Hansen T.F., Garm Spindler K.L., Andersen R.F., Lindebjerg J., Brandslund I., Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomic. J. 2011, 11:53-60.
15. Hansen T., Sorensen F., Lindebjerg J., Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012, 12:83.
16. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
17. Jiang J., Zheng X., Xu X., Zhou Q., Yan H., Zhang X., Lu B., Wu C., Ju J. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One 2011, 6:e23271.
18. Kohne C.H., van Cutsem E., Wils J., Bokemeyer C., El-Serafi M., Lutz M.P., Lorenz M., Reichardt P., Ruckle-Lanz H., Frickhofen N., Fuchs R., Mergenthaler H.G., Langenbuch T., Vanhoefer U., Rougier P., Voigtmann R., Muller L., Genicot B., Anak O., Nordlinger B. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. 2005, 23:4856-4865.
19. Kurokawa K., Tanahashi T., Iima T., Yamamoto Y., Akaike Y., Nishida K., Masuda K., Kuwano Y., Murakami Y., Fukushima M., Rokutan K. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J. Gastroenterol. 2012, 47:883-895.
20. Li J., Smyth P., Flavin R., Cahill S., Denning K., Aherne S., Guenther S.M., O'Leary J.J., Sheils O. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007, 7:36.
21. Mestdagh P., Van Vlierberghe P., De Weer A., Muth D., Westermann F., Speleman F., Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009, 10:R64.
22. Michaelis L.C., Ratain M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nature reviews. Cancer 2006, 6:409-414.
23. Nakajima G., Hayashi K., Xi Y., Kudo K., Uchida K., Takasaki K., Yamamoto M., Ju J. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genom. Proteom. 2006, 3:317-324.
24. Pfeiffer P., Qvortrup C., Eriksen J.G. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007, 26:3661-3678.
25. Qvortrup C., Jensen B.V., Fokstuen T., Nielsen S.E., Keldsen N., Glimelius B., Bjerregaard B., Mejer J., Larsen F.O., Pfeiffer P. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Annals of oncology. Off. J. Eur. Soc. Med. Oncol./ESMO 2010, 21:87-91.
26. Saldanha A.J. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248.
27. Schepeler T., Reinert J.T., Ostenfeld M.S., Christensen L.L., Silahtaroglu A.N., Dyrskjøt L., Wiuf C., Sørensen F.J., Kruhøffer M., Laurberg S., Kauppinen S., Ørntoft T.F., Andersen C.L. Diagnostic and prognostic MicroRNAs in Stage II Colon Cancer. Cancer Res. 2008, 68:6416-6424.
28. Song B., Wang Y., Xi Y., Kudo K., Bruheim S., Botchkina G.I., Gavin E., Wan Y., Formentini A., Kornmann M., Fodstad O., Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
29. Suraweera N., Duval A., Reperant M., Vaury C., Furlan D., Leroy K., Seruca R., Iacopetta B., Hamelin R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123:1804-1811.
30. Takahashi M., Cuatrecasas M., Balaguer F., Hur K., Toiyama Y., Castells A., Boland C.R., Goel A. The clinical significance of MiR-148a as a predictive Biomarker in patients with advanced colorectal cancer. PLoS One 2012, 7:e46684.
31. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in Solid tumors. J. Natl. Cancer Inst. 2000, 92:205-216.
32. Thorsen K., Schepeler T., Oster B., Rasmussen M., Vang S., Wang K., Hansen K., Lamy P., Pedersen J., Eller A., Mansilla F., Laurila K., Wiuf C., Laurberg S., Dyrskjot L., Orntoft T., Andersen C. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics 2011, 12:505.
33. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22:229-237.
34. Urbich C., Kaluza D., Fromel T., Knau A., Bennewitz K., Boon R.A., Bonauer A., Doebele C., Boeckel J.N., Hergenreider E., Zeiher A.M., Kroll J., Fleming I., Dimmeler S. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012, 119:1607-1616.
35. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., Sumani K.M., Alder H., Amadori D., Patel T., Nuovo G.J., Fishel R., Croce C.M. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U S A 2010, 107:21098-21103.
36. Van Cutsem E., Nordlinger B., Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of oncology. Off. J. Eur. Soc. Med. Oncol./ESMO 2010, 21(Suppl 5):v93-v97.
37. Voinnet O. Origin, biogenesis, and activity of plant microRNAs. Cell 2009, 136:669-687.
38. Wang B.D., Kline C.L., Pastor D.M., Olson T.L., Frank B., Luu T., Sharma A.K., Robertson G., Weirauch M.T., Patierno S.R., Stuart J.M., Irby R.B., Lee N.H. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol. Cancer 2010, 9:98.
39. Wang S., Wang L., Zhu T., Gao X., Li J., Wu Y., Zhu H. Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics 2010, 11:163.
40. Wilkerson J., Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 2009, 15:379-385.
41. Xi Y., Nakajima G., Gavin E., Morris C.G., Kudo K., Hayashi K., Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13:1668-1674.
42. Xu K., Liang X., Cui D., Wu Y., Shi W., Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol. Carcinog. 2011.
43. Yang J.S., Phillips M.D., Betel D., Mu P., Ventura A., Siepel A.C., Chen K.C., Lai E.C. Widespread regulatory activity of vertebrate microRNA species. RNA 2011, 17:312-326.
44. Zhou Q., Gallagher R., Ufret-Vincenty R., Li X., Olson E.N., Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼27∼24 clusters. Proc. Natl. Acad. Sci. U S A 2011, 108:8287-8292.